
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Biomotion Sciences Warrant (SLXNW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: SLXNW (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -59.62% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.12 | 52 Weeks Range 0.01 - 0.18 | Updated Date 06/5/2025 |
52 Weeks Range 0.01 - 0.18 | Updated Date 06/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -193.54% | Return on Equity (TTM) -116.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 996278 |
Shares Outstanding - | Shares Floating 996278 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Biomotion Sciences Warrant
Company Overview
History and Background
It is impossible to provide the history of Biomotion Sciences Warrant, including its founding year, significant milestones, and evolution over time, as the ticker is a warrant not a company and therefore will not have a company history.
Core Business Areas
Leadership and Structure
It is impossible to outline Biomotion Sciences Warrant's leadership team and organizational structure as it is a warrant, not a company
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
Warrants are derivative securities that give the holder the right, but not the obligation, to purchase the underlying stock at a specified price (the exercise price) within a certain timeframe. Their value is derived from the underlying stock's performance and market volatility. The warrant market is tied to the overall stock market's health and investor sentiment.
Positioning
Biomotion Sciences Warrant's position is dependent on the underlying stock (if the underlying stock exist) performance and market sentiment towards that specific stock. It offers leveraged exposure to the underlying stock's price movements, both positive and negative. The warrant's potential upside is high if the underlying stock performs well, but the risk of total loss is also significant.
Total Addressable Market (TAM)
The TAM for warrants is difficult to quantify precisely, as it's a subset of the overall equity derivatives market. The TAM is influenced by factors like investor appetite for leverage, market volatility, and the number of companies offering warrants. Biomotion Sciences Warrant's potential within this TAM depends on the underlying stock's performance and its attractiveness to investors seeking leveraged exposure.
Upturn SWOT Analysis
Strengths
- Leveraged exposure to the underlying stock
- Potential for high returns with smaller initial investment
- Can be used for hedging purposes
Weaknesses
- High risk of total loss if the underlying stock doesn't perform well
- Time decay as the expiration date approaches
- Value is highly sensitive to the underlying stock's price volatility
Opportunities
- Capitalize on potential growth of the underlying stock
- Take advantage of market volatility to generate profits
- Use warrants as part of a broader investment strategy
Threats
- Decline in the underlying stock's price
- Increase in market volatility can erode warrant value.
- Expiration date approaching can cause rapid value decay
Competitors and Market Share
Key Competitors
Competitive Landscape
Since the ticker is a warrant, not a company, it does not have market share or competitors.
Growth Trajectory and Initiatives
Historical Growth: Warrant performance is tied to the underlying asset, and has no historical growth on it's own.
Future Projections: Future projections are entirely dependent on the trajectory of the underlying stock, and are difficult to assess with certainty.
Recent Initiatives: Since the ticker is a warrant, not a company, it will not have recent strategic initiatives.
Summary
Biomotion Sciences Warrant is a derivative security that provides leveraged exposure to its underlying stock. Its value is highly sensitive to the performance of the underlying asset and market volatility. The warrant offers high potential returns, but also carries a significant risk of total loss. Investors should carefully assess the underlying stock's prospects and their own risk tolerance before investing in this warrant.
Peer Comparison
Sources and Disclaimers
Data Sources:
- General market knowledge
- Financial databases for stock and warrant information
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Warrants are complex financial instruments and carry a high degree of risk. Consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomotion Sciences Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-08-16 | Chairman & CEO Mr. Ilan Hadar M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://silexion.com |
Full time employees 11 | Website https://silexion.com |
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.